Current Report Filing (8-k)
10 January 2023 - 12:24AM
Edgar (US Regulatory)
0001708527 false 0001708527 2023-01-09
2023-01-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
January 9, 2023
AZIYO BIOLOGICS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-39577 |
|
47-4790334 |
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
12510 Prosperity Drive,
Suite 370
Silver Spring,
MD
20904
(Address of principal executive offices) (Zip Code)
(240)
247-1170
(Registrant’s telephone number, include area code)
N/A
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
|
¨ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
|
¨ |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
¨ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the
Act:
Title of
each class |
|
Trading
Symbols |
|
Name of
each exchange on which
registered |
Class A Common Stock, $0.001 par value per share |
|
AZYO |
|
The
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
x
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised
financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act.
Item 2.02. |
Results of Operation and
Financial Condition. |
On January 9, 2023, Aziyo Biologics, Inc. (the “Company”) issued a
press release announcing its preliminary net sales results for the
fourth quarter and full year ended December 31, 2022. A copy of the
Company’s press release is furnished as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by
reference.
The information in this Current Report on Form 8-K (including
Exhibit 99.1) shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that
Section, nor shall it be deemed to be incorporated by reference
into any filing of the Company under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such filing.
|
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
AZIYO BIOLOGICS, INC.
|
|
|
|
Date:
January 9, 2023 |
By: |
/s/ Matthew Ferguson
|
|
|
Matthew
Ferguson |
|
|
Chief
Financial Officer |
Aziyo Biologics (NASDAQ:AZYO)
Historical Stock Chart
From Mar 2023 to Mar 2023
Aziyo Biologics (NASDAQ:AZYO)
Historical Stock Chart
From Mar 2022 to Mar 2023